|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 98.12 CHF | +1.15% |
|
+1.53% | +10.65% |
| 04:46pm | Novartis Reports 'Significant' Improvements in Study of Fabhalta to Treat PNH | MT |
| 02:06pm | Novartis: Fabhalta approved for a new population | CF |
| Capitalization | 23TCr 20TCr 19TCr 17TCr 32TCr 19,81200Cr 36TCr 2,21400Cr 86TCr 9,07100Cr 87TCr 85TCr 33,53500Cr | P/E ratio 2025 * |
17x | P/E ratio 2026 * | 15.7x |
|---|---|---|---|---|---|
| Enterprise value | 25TCr 22TCr 20TCr 18TCr 34TCr 21,18000Cr 38TCr 2,36700Cr 92TCr 9,69700Cr 93TCr 91TCr 35,85000Cr | EV / Sales 2025 * |
4.56x | EV / Sales 2026 * | 4.37x |
| Free-Float |
87.19% | Yield 2025 * |
3.34% | Yield 2026 * | 3.47% |
More valuation ratios
* Estimated data
More news
Last Transcript: Novartis AG
More recommendations
More press releases
More news
| 1 day | +0.64% | ||
| 1 week | +1.06% | ||
| Current month | +3.89% | ||
| 1 month | +6.56% | ||
| 3 months | +1.43% | ||
| 6 months | +10.94% | ||
| Current year | +10.14% |
| 1 week | 96.5 |  | 97.99 |
| 1 month | 87.89 | | 97.99 |
| Current year | 81.1 | | 101.84 |
| 1 year | 81.1 | | 102.72 |
| 3 years | 73.32 | | 102.72 |
| 5 years | 70.42 | | 102.72 |
| 10 years | 65.09 | | 103.2 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 49 | 01/02/2018 | |
| Director of Finance/CFO | 60 | 24/04/2013 | |
Shreeram Aradhye
CTO | Chief Tech/Sci/R&D Officer | 63 | 16/05/2022 |
| Director | Title | Age | Since |
|---|---|---|---|
Nancy Andrews
BRD | Director/Board Member | 66 | 01/01/2015 |
Liz Doherty
BRD | Director/Board Member | 68 | 01/01/2016 |
Ton Büchner
BRD | Director/Board Member | 60 | 01/01/2016 |
| Name | Weight | AuM | 1st Jan change | |
|---|---|---|---|---|
| 10.4% | 121 M€ | -.--% | - | |
| 5.57% | 21 M€ | +0.90% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +0.63% | +1.06% | +3.20% | +18.01% | 23TCr | ||
| +0.18% | +5.58% | -6.61% | +172.25% | 73TCr | ||
| -0.76% | +1.33% | +5.79% | -10.02% | 37TCr | ||
| +0.58% | +5.76% | -47.59% | +34.67% | 35TCr | ||
| +1.06% | +2.22% | +14.19% | +33.73% | 34TCr | ||
| +0.46% | +1.34% | +11.42% | -12.27% | 26TCr | ||
| +0.62% | +2.52% | -12.00% | +12.20% | 23TCr | ||
| -1.27% | +2.62% | -39.08% | -7.87% | 20TCr | ||
| -0.55% | +1.67% | -2.96% | +21.58% | 16TCr | ||
| +0.74% | +4.66% | -12.67% | -51.01% | 14TCr | ||
| Average | +0.22% | +3.20% | -8.63% | +21.13% | 30.14TCr | |
| Weighted average by Cap. | +0.14% | +3.64% | -7.88% | +47.57% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 5.43TCr 4.73TCr 4.45TCr 4.01TCr 7.42TCr 4,64000Cr 8.33TCr 52TCr 20TCr 2,12400Cr 20TCr 20TCr 7,85300Cr | 5.51TCr 4.8TCr 4.51TCr 4.07TCr 7.53TCr 4,70600Cr 8.45TCr 53TCr 20TCr 2,15500Cr 21TCr 20TCr 7,96600Cr |
| Net income | 1.38TCr 1.2TCr 1.13TCr 1.02TCr 1.89TCr 1,18200Cr 2.12TCr 13TCr 5.11TCr 54TCr 5.19TCr 5.08TCr 2,00000Cr | 1.45TCr 1.26TCr 1.19TCr 1.07TCr 1.98TCr 1,24000Cr 2.23TCr 14TCr 5.37TCr 57TCr 5.44TCr 5.33TCr 2,09900Cr |
| Net Debt | 1.6TCr 1.39TCr 1.31TCr 1.18TCr 2.19TCr 1,36700Cr 2.45TCr 15TCr 5.92TCr 63TCr 6TCr 5.88TCr 2,31400Cr | 905.47Cr 788.48Cr 742.25Cr 668.49Cr 1.24TCr 77TCr 1.39TCr 8.65TCr 3.35TCr 35TCr 3.4TCr 3.33TCr 1,31000Cr |
More financial data
* Estimated data
Employees
75,883
Sector
Pharmaceuticals
Calendar
| Date | Price | Change | Volume |
|---|---|---|---|
| 12/25/12 | 98.15 CHF | +1.19% | 19,24,835 |
| 11/25/11 | 97.00 CHF | -0.58% | 27,37,002 |
| 10/25/10 | 97.57 CHF | +0.50% | 24,45,869 |
| 06/25/06 | 97.08 CHF | +0.42% | 22,07,868 |
| 05/25/05 | 96.67 CHF | +0.66% | 23,18,933 |
Delayed Quote Swiss Exchange, June 12, 2025 at 06:20 pm IST
More quotes
Sell
Buy
Mean consensus
HOLD
Number of Analysts
21
Last Close Price
118.33USD
Average target price
118.73USD
Spread / Average Target
+0.34%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- NOVN Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition